Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of venglustat versus usual standard of care in Fabry disease with left ventricular hypertrophy
jRCT2071220022Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Nov 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial in Fabry disease (FD) comparing Venglustat with Usual standard of care (2 arms). Primary endpoint: Slope of left ventricular mass index. Started Nov 2022; status: active, not recruiting.
02
Drugs
venglustat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on jRCT2071220022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220022.